Global healthtech company Harrison.ai has completed a significant $112 million Series C funding round, bringing its total capital raised to over $240 million. The round was co-led by Aware Super, ECP, and existing investor Horizons Ventures, with participation from new investors including Australia's National Reconstruction Fund Corporation (NRFC), Ord Minnett, and Wollemi Capital Group, alongside existing investors Blackbird Ventures and Alpha JWC Ventures.
The company's AI technology focuses on analyzing medical images, including CT scans and X-rays, to enhance clinicians' ability to detect cancer and other critical illnesses. The platform has demonstrated remarkable effectiveness in early detection, with studies showing their AI chest radiography system can facilitate lung cancer diagnosis up to 32% earlier than traditional methods.
Harrison.ai's solution addresses two critical healthcare challenges: the global shortage of skilled radiologists and pathologists, and disparities in healthcare access across developed and developing regions. By augmenting human capabilities and providing remote access to diagnostic expertise, the technology aims to democratize advanced diagnostic services.
The company has achieved significant regulatory milestones, securing 12 FDA clearances, with one of its CT Brain algorithms receiving FDA Breakthrough Device Designation and Medicare reimbursement through the New Technology Add-on Payment (NTAP). These achievements have positioned Harrison.ai for expansion into the United States, where it is establishing operations in Boston.
The funding will support Harrison.ai's global growth strategy, particularly its expansion into the US market, while continuing development in the UK, EMEA, and APAC regions. The company has already demonstrated its international impact through strategic partnerships, including integration into the Danish public healthcare system and deployment across Hong Kong's public accident and emergency systems for CT Brain scans.
This investment round represents a significant step forward in Harrison.ai's mission to improve diagnostic accuracy and reduce treatment delays through AI-powered solutions, ultimately working toward more equitable and effective healthcare delivery worldwide.
Click here for the original news story.